TACE inhibition: a new approach to treating inflammation.

Abstract

Clinical trials showing the benefits of reducing the effects of TNF- alpha in rheumatoid arthritis have highlighted the key role of the cytokine TNF- alpha in this inflammatory condition. A new approach to reducing the effects of TNF- alpha is to decrease its synthesis by inhibiting TNF- alpha converting enzyme with GW3333. In rat models of arthritis, GW3333 has some beneficial effects. Further longer-term studies of GW3333 in animal models are required to determine whether its benefit is maintained. TACE inhibition may represent a new approach to treating inflammation.

• Authors: Sheila A Doggrell
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 11 Issue 7 Pg. 1003-6 (Jul 2002) ISSN: 1354-3784 [Print] England
• PMID: 12084010 (Publication Type: Journal Article)

Chemical References

• Aminopyridines
• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal
• Dipeptides
• GW 3333
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Infliximab
• ADAM Proteins
• Metalloendopeptidases
• ADAM17 Protein
• ADAM17 protein, human
• Adam17 protein, rat
• Etanercept

Topics

• ADAM Proteins
• ADAM17 Protein
• Aminopyridines (chemistry, pharmacology, therapeutic use)
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Arthritis, Experimental (drug therapy)
• Arthritis, Rheumatoid (drug therapy)
• Clinical Trials as Topic
• Dipeptides (chemistry, pharmacology, therapeutic use)
• Drug Therapy, Combination
• Etanercept
• Humans
• Immunoglobulin G (therapeutic use)
• Infliximab
• Metalloendopeptidases (antagonists & inhibitors, biosynthesis, blood)
• Rats
• Receptors, Tumor Necrosis Factor (therapeutic use)